Navigation Links
NexGenix Pharmaceuticals Presents Data on a Novel Small Molecule Inhibitor of Heat Shock Protein 90 (Hsp90) at the GTCbio Cancer Drugs Research & Development Conference
Date:2/22/2008

NEW YORK, Feb. 22 /PRNewswire/ -- NexGenix Pharmaceuticals, presented data on its Hsp90 inhibitor program today at the GTCBio 5th Annual Cancer Drugs Research & Development Conference taking place in Phoenix, Arizona. The company presented data on NXD30001, one of several novel, radicicol-based Hsp90 inhibitors in its compound series.

NXD30001 demonstrated efficacy in breast cancer tumor xenograft models without evidence for liver and kidney toxicity. The potency, tolerability, pharmacokinetic and pharmacodynamic properties of NXD30001 and its derivatives indicate that it, or an analog, may be useful in the treatment of breast and other forms of cancer with an improved dosing and therapeutic window compared to 17AAG, the first-in-class Hsp90 inhibitor currently in Phase 2 clinical trials for cancer.

The compound series appears to bind Hsp90 in a different mode than 17AAG or radicicol and exhibit higher affinity to Hsp90 than radicicol. NXD30001 and its analogs efficiently inhibit cell proliferation and deplete multiple Hsp90 client proteins such as Her2, Akt, c-Raf, Cdk4, and Cyclin D1 in Her2- overexpressing breast and other cancer cell lines at low nanomolar concentrations. Pharmacokinetic studies demonstrate that NXD30001 can achieve potential therapeutic levels via intraperitoneal (i.p.) dosing and that the compound accumulates in tumors at above micromolar concentrations.

Tumor pharmacodynamic analysis demonstrated depletion of multiple Hsp90 client proteins, including Her2, after a single dose; these client proteins remained undetectable for more than 2 days, consistent with the pharmacokinetic tumor data.

"A number of analogs with activity similar to or better than NXD30001 have been synthesized and are being evaluated for oral bioavailability, tolerability, and efficacy," stated Allan Rubenstein, MD, CEO of NexGenix. "Our intent is to progress an i.v. formulation of NXD30001 into IND-enabling studies for breast cancer, and
'/>"/>

SOURCE NexGenix Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... , Dec. 22, 2014 Research and ... the addition of the "Investment Analysis of ... to their offering. ... in the US medical device sector identifies the ... and venture capital investments, and mergers and acquisitions. ...
(Date:12/22/2014)... Cyberonics, Inc. (NASDAQ: CYBX ), a ... of epilepsy, today announced it will participate in the 33 ... 14, 2015, in San Francisco . ... Officer, will speak at 11:00 AM Pacific Time.  A live ... on the Investor Relations link on the Cyberonics home page ...
(Date:12/22/2014)... /PRNewswire/ -- RXi Pharmaceuticals Corporation (NASDAQ: RXII ... and commercializing innovative therapies addressing major unmet medical ... open letter to shareholders from President & CEO, ... Dear RXi Shareholders, In the ... posted on certain social media sites seem to ...
Breaking Medicine Technology:Investment Analysis of the US Medical Device Sector 2RXi Pharmaceuticals Issues Open Letter to Shareholders 2RXi Pharmaceuticals Issues Open Letter to Shareholders 3RXi Pharmaceuticals Issues Open Letter to Shareholders 4RXi Pharmaceuticals Issues Open Letter to Shareholders 5RXi Pharmaceuticals Issues Open Letter to Shareholders 6
... 9, 2012  CareFusion Corporation (NYSE: CFN ) today ... this afternoon by Chairman and CEO Kieran T. Gallahue at ... said it expects revenue for its second fiscal quarter, ended ... and operating income to be $141 million to $146 million. ...
... Jan. 9, 2012 Ampio Pharmaceuticals, Inc. (NASDAQ: ... that discovers and develops new uses for previously approved ... Wingerter would be granted a compassionate leave from all ... to serious illnesses afflicting his closest family members.  The ...
Cached Medicine Technology:CareFusion Announces Preliminary Second Quarter Results 2CareFusion Announces Preliminary Second Quarter Results 3CareFusion Announces Preliminary Second Quarter Results 4CareFusion Announces Preliminary Second Quarter Results 5CareFusion Announces Preliminary Second Quarter Results 6Executive Changes at Ampio 2Executive Changes at Ampio 3
(Date:12/24/2014)... Dr. Ronald Receveur, a New ... dental implants in a day, has written ... overusing teeth-whitening treatments. , In his blog published ... Receveur writes that overusing teeth-whitening treatments can lead to ... enamel. , “Because teeth-whitening treatments are available ...
(Date:12/24/2014)... News) -- Longer and colder body cooling does not reduce ... from a lack of oxygen, a new study finds. ... condition -- called hypoxic ischemic encephalopathy -- can be reduced ... Fahrenheit) for 72 hours, experts say. Research has shown ... so this study examined if the same would be true ...
(Date:12/22/2014)... December 22, 2014 B. E. Smith, ... healthcare providers, has been retained to lead a national ... Medical Center in Oceanside, Calif. The top ... E. Smith has recently placed more than 900 healthcare ... a community owned, 397-bed, Gold Seal-approved, full-service acute-care hospital ...
(Date:12/22/2014)... 22, 2014 Sagacious Consultants, the premier ... subscription option to their ad hoc report writing service ... Customers can sign up for an annual subscription and ... month at a deeply discounted hourly rate. , ... has a progressively discounted rate. Subscription hours are contracted ...
(Date:12/22/2014)... News) -- U.S. and state health officials are investigating ... killed at least four people and sickened 28 others ... commercially produced, prepackaged caramel apples until more information becomes ... said in a news release. As of Dec. ... with the outbreak strains of the bacteria Listeria ...
Breaking Medicine News(10 mins):Health News:New Albany Dentist Weighs In On New Trend of Overbleaching Teeth 2Health News:New Albany Dentist Weighs In On New Trend of Overbleaching Teeth 3Health News:Greater Cooling of Oxygen-Deprived Infants Fails to Improve Survival 2Health News:Tri-City Medical Center Retains B. E. Smith to Recruit New Chief Compliance Officer 2Health News:Tri-City Medical Center Retains B. E. Smith to Recruit New Chief Compliance Officer 3Health News:Sagacious Consultants’ New Subscription Packages Offer Customers Additional Report Writing Options 2Health News:Sagacious Consultants’ New Subscription Packages Offer Customers Additional Report Writing Options 3Health News:CDC Warns of Listeria Danger From Caramel Apples 2
... Education Secretary,Gerald L. Zahorchak today issued the ... approving House Bill 1841, legislation to create,a statewide ... House Education Committee took a major step today ... care for educators,and cut down on teacher strikes," ...
... million Americans have survived a heart attack or have ... one cause of death in the United States. In ... diet and exercise, are known to reduce the risk ... proportion of heart attack survivors do not follow their ...
... Helps Drive Growth in ... Interactive Patient Care, ... of Interactive Patient Care (IPC) solutions, today announced that,Irwin Studen ... chief financial officer. With extensive experience in the,healthcare and technology ...
... back vivid, 30-year-old memories for patient, researchers say , , ... (DBS) may help improve memory, suggests a Canadian study ... prompted detailed memories in a patient. , DBS ... -- is used to treat Parkinson,s disease and other ...
... doctors as a hormone that boosts red-blood-cell production. Now, ... ophthalmologist at Children,s Hospital Boston, shows it also keeps blood ... not only add a new function to the hormone, but ... to patients with diseases affected by abnormal blood-vessel growth, such ...
... Pharmaceutical,Laboratories, Ltd. (Amex: CPD ) announced today ... mg (Pantoprazole Sodium,DR), which is AB-rated to Wyeth,s ... Ltd. (Sun Pharma). Sun Pharma recently received,approval from ... its Abbreviated,New Drug Application (ANDA) for generic Protonix(R), ...
Cached Medicine News:Health News:UMass Medical School study finds patients diagnosed with coronary heart disease continue poor diets 2Health News:UMass Medical School study finds patients diagnosed with coronary heart disease continue poor diets 3Health News:Irwin Studen Joins GetWellNetwork as Senior Vice President and Chief Financial Officer 2Health News:Irwin Studen Joins GetWellNetwork as Senior Vice President and Chief Financial Officer 3Health News:Deep Brain Stimulation May Improve Recall 2Health News:Anemia treatment may be a double-edged sword 2Health News:Anemia treatment may be a double-edged sword 3Health News:Caraco Pharmaceutical Laboratories Ltd. to Market Generic Protonix(R) 2Health News:Caraco Pharmaceutical Laboratories Ltd. to Market Generic Protonix(R) 3
... concave seats and standard-sized backrests with ... seats, backrests, armrests, and casters and ... for the following environments: industry, education, ... care and office. • With polished ...
... Basic ergonomic chairs with concave ... support • Select options like seats, ... • BTP/1Q-PAL chairs are recommended for ... clean room, static control, health care ...
... Basic ergonomic chairs with concave ... support • Select options like seats, ... • BTP/1Q-PAL chairs are recommended for ... clean room, static control, health care ...
... ergonomic chairs with concave seats and ... Select options like seats, backrests, armrests, ... chairs are recommended for the following ... static control, health care and office. ...
Medicine Products: